Results 11 to 20 of about 48,421 (285)

A case of cardiac amyloidosis incidentally detected by bone scintigraphy [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2021
A 73-year-old man with lung cancer underwent bone scintigraphy for disease staging. Diffuse myocardial technetium hydroxymethylene diphosphonate (99mTc-HMDP) uptake was incidentally found.
Hiroki Tanaka, Makoto Hosono, Mitsunori Kanagaki, Marina Shimizu, Naoko Matsubara, Kazuna Kawabata, Tadashi Miyamoto, Kazumi Itoi   +7 more
doaj   +1 more source

Evaluation of a new ELISA assay for monoclonal free‐light chain detection in patients with cardiac amyloidosis

eJHaem, 2022
The causal protein of amyloid light‐chain (AL) amyloidosis is a monoclonal immunoglobulin free light chain (mFLC), which must be quantified in the serum for patient diagnosis and monitoring.
Hajer Abroud, Asma Beldi‐Ferchiou, Vincent Audard, François Lemonnier, Fabien Le Bras, Karim Belhadj, Anissa Moktefi, Elsa Poullot, Khalil El Karoui, Jehan Dupuis, Alizée Maarek, Louise Roulin, Marie‐Hélène Delfau‐Larue, Silvia Oghina, Mounira Kharoubi, Mélanie Bézard, Amira Zaroui, Thibaud Damy, Valérie Molinier‐Frenkel   +18 more
doaj   +1 more source

Restrictive Atrial Dysfunction in Cardiac Amyloidosis: Differences between Immunoglobulin Light Chain and Transthyretin Cardiac Amyloidosis Patients

Biomedicines, 2022
Background: In cardiac amyloidosis, the prevalence of thromboembolic events and atrial fibrillation is higher in transthyretin amyloidosis compared to immunoglobulin light chain amyloidosis.
Mathijs O. Versteylen, Maaike Brons, Arco J. Teske, Marish I. F. J. Oerlemans   +3 more
doaj   +1 more source

Nuclear Imaging for the Diagnosis of Cardiac Amyloidosis in 2021

Diagnostics, 2021
Cardiac amyloidosis is caused by the deposition of misfolded protein fibrils into the extracellular space of the heart. The diagnosis of cardiac amyloidosis remains challenging because of the heterogeneous manifestations of the disease.
Weijia Li, Dipan Uppal, Yu Chiang Wang, Xiaobo Xu, Damianos G. Kokkinidis, Mark I. Travin, James M. Tauras   +6 more
doaj   +1 more source

Frequency of and Prognostic Significance of Cardiac Involvement at Presentation in Hereditary Transthyretin-Derived Amyloidosis and the Value of N-Terminal Pro-B-Type Natriuretic Peptide [PDF]

, 2018
The aim of this study is to assess the prevalence of cardiac involvement in hereditary transthyretin-derived (ATTRm) amyloidosis at the time of diagnosis and to determine the diagnostic and clinical value of N-terminal pro-B-type natriuretic peptide (NT ...
Blokzijl, Hans, Hazenberg, Bouke P C, Klaassen, Sebastiaan H C, Nienhuis, Hans L A, Tromp, Jasper, van den Berg, Maarten P, van der Meer, Peter, van Veldhuisen, Dirk J   +7 more
core   +6 more sources

Utility and pitfalls of the electrocardiogram in the evaluation of cardiac amyloidosis

Annals of Noninvasive Electrocardiology, 2022
Background Cardiac amyloidosis is a protein misfolding disorder involving deposition of amyloid fibril proteins in the heart. The associated fibrosis of the conduction tissue results in conduction abnormalities and arrhythmias.
Perryn Lin Fei Ng, Yoke Ching Lim, Lauren Kay Mance Evangelista, Raymond Ching Chiew Wong, Ping Chai, Ching Hui Sia, Hoi Yin Loi, Tiong Cheng Yeo, Weiqin Lin   +8 more
doaj   +1 more source

Left Ventricular Structure and Function in Transthyretin-Related Versus Light-Chain Cardiac Amyloidosis

Circulation, 2014
Candida Cristina Quarta, Scott D. Solomon, Imran Uraizee, Jenna Kruger, Simone Longhi, Marinella Ferlito, Christian Gagliardi, Agnese Milandri, Claudio Rapezzi, Rodney H. Falk   +9 more
openalex   +4 more sources

Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2020
Background Outcomes data in patients with cardiac amyloidosis after implantable cardioverter‐defibrillator (ICD) implantation are limited. We compared outcomes of patients with ICDs implanted for cardiac amyloidosis versus nonischemic cardiomyopathies ...
Angela Y. Higgins, Amarnath R. Annapureddy, Yongfei Wang, Karl E. Minges, Rachel Lampert, Lynda E. Rosenfeld, Daniel L. Jacoby, Jeptha P. Curtis, Edward J. Miller, James V. Freeman   +9 more
doaj   +1 more source

Transthyretin cardiac amyloidosis in patients after TAVR: clinical and echocardiographic findings and long term survival

ESC Heart Failure, 2021
Aims The aim of this study was to examine the prevalence of amyloid transthyretin (ATTR) cardiac amyloidosis in patients 1–2 years after trans‐catheter aortic valve replacement (TAVR) and to assess their clinical and echocardiographic outcome and long ...
Sara Shimoni, Meital Zikri, Dan Haberman, Shay Livschitz, Sagi Tshori, Yacov Fabricant, Valery Meledin, Gera Gandelman, Sorel Goland, Jacob George   +9 more
doaj   +1 more source

Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome [PDF]

, 2013
Background Cardiac amyloidosis is a fatal disease whose prognosis and treatment rely on identification of the amyloid type. In our aging population transthyretin amyloidosis (ATTRwt) is common and must be differentiated from other amyloid types.
Banypersad, SM, Dungu, J, Gibbs, SD, Gilbertson, JA, Gillmore, JD, Hawkins, PN, Lachmann, HJ, McCarthy, CA, Petrie, A, Pinney, JH, Rowczenio, D, Sattianayagam, P, Venner, CP, Wassef, N, Wechalekar, A, Whelan, CJ   +15 more
core   +1 more source